MOMIPP

MOMIPP, a macropinocytosis inducer, is a PIKfyve inhibitor. MOMIPP penetrates the blood-brain barrier (BBB). In Vitro MOMIPP can induce intense macropinocytosis, leading to methuosis in cultured glioblastoma cells at low micromolar concentrations. In U373 and Hs683 cell lines, 3 µM for MOMIPP induces cell vacuolization. MOMIPP (10 μM) causes early disruptions of glucose uptake and glycolytic metabolism. MOMIPP selectively activates the JNK1/2 stress kinase pathway, resulting in phosphorylation of c-Jun, Bcl-2 and Bcl-xL. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: U251 cells Concentration: 10 μM Incubation Time: 4 h or 24 h Result: Activated the JNK stress kinase pathway. In Vivo MOMIPP (80 mg/kg; i.p.; once daily; for 15 consecutive days) shows moderately effective in suppressing progression of intracerebral glioblastoma xenografts. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Athymic CrTac:NCR-Foxn1 mice (female, 7-8 weeks)Dosage: 80 mg/kg Administration: i.p.; once daily; for 15 consecutive days Result: Suppressed progression of intracerebral glioblastoma xenografts.

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet